Clinical Trial Update: Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating two different 6 mg dosing regimens of brolucizumab for neovascular age-related macular degeneration, reporting on efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Brolucizumab (Beovu) (brolucizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Age-related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2025-01-27